Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
...roject Management Angiogenesis.
Kristian Jensen joins Pieris from Merck Serono, where he spent almost
three years establishing and managing its phage
display antibody facility in
Geneva, Switzerland. Prior to Merck Serono, he obtained his research
management experience during four years as Group Lea...
MicroPhage Successfully Completes Beta Trial for Rapid MRSA Test
...sample is challenged with an
antibiotic. Because phages depend on host bacteria for growth, any compound
that kills or inhibits the microbe will stop phage
growth. Only resistant
strains allow multiplication of phages and yield a positive signal on the
detector strip. Further information about the techno...
Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
... Athera has identified
an exciting potential opportunity for therapeutic antibody treatment of
"The strength of Dyax's phage
display technology, screening
capabilities and expertise in drug discovery make them an excellent partner
to advance our cardiovascular research progr...
Viral Enzyme Recruited in Fight Against Ear Infection
...lled phages to break out of bacteria they infect by using
a special enzyme to destroy the cell walls.
The success of the new treatment, which uses a phage
called lysin to kill S. pneumonia, suggests that the strategy could
significantly reduce the incidence of acute otitis media in the
Preclinical Data on Cytogen's Technology to be Reported at the AACR
... 8:00 AM -12:00 PM
Abstract #645: Studies with long random phage
Epitope-specific peptides recapitulate antibody complement...LGA) nanoparticles coated with
active-transport peptides derived from phage
The abstracts are available and can be viewed on-line at no ch...
DX-88 for Hereditary Angioedema Meets Primary and Secondary
Endpoints in Phase 3 Trial (EDEMA3)
...(CTS), including CABG and heart valve replacement or repair
Dyax identified DX-88 and other compounds in its pipeline using
its patented phage
display technology, which rapidly selects
compounds that bind with high affinity and specificity to
therapeutic targets. Dyax leverages this technolog...